{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:08:26Z","timestamp":1793207306704,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00296-018-4086-1","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T09:53:56Z","timestamp":1530006836000},"page":"1699-1704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition"],"prefix":"10.1007","volume":"38","author":[{"given":"Dario","family":"Camellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Soldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Cimmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"4086_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","volume":"372","author":"C Salvarani","year":"2008","unstructured":"Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372:234\u2013245","journal-title":"Lancet"},{"key":"4086_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3899\/jrheum.091185","volume":"37","author":"K Hagihara","year":"2010","unstructured":"Hagihara K, Kawase I, Tanaka T, Kishimoto T (2010) Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 37:1075\u20131076","journal-title":"J Rheumatol"},{"key":"4086_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.semarthrit.2013.01.003","volume":"43","author":"P Macchioni","year":"2013","unstructured":"Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R et al (2013) Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 43:113\u2013118","journal-title":"Semin Arthritis Rheum"},{"key":"4086_CR4","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/acr.21750","volume":"64","author":"S Unizony","year":"2012","unstructured":"Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B et al (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64:1720\u20131729","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4086_CR5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S et al (2016) Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis 75:1506\u20131510","journal-title":"Ann Rheum Dis"},{"key":"4086_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C et al (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a european league against rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71:484\u2013492","journal-title":"Ann Rheum Dis"},{"key":"4086_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/rheumatology\/39.8.883","volume":"39","author":"S Kalke","year":"2000","unstructured":"Kalke S, Mukerjee D, Dasgupta B (2000) A study of the health assessment questionnaire to evaluate functional status in polymyalgia rheumatica. Rheumatology 39:883\u2013885","journal-title":"Rheumatology"},{"key":"4086_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Bird HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63:1279\u20131283","journal-title":"Ann Rheum Dis"},{"key":"4086_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/rheumatology\/keq450","volume":"51","author":"D Camellino","year":"2012","unstructured":"Camellino D, Cimmino MA (2012) Imaging of polymyalgia rheumatica: Indications on its pathogenesis, diagnosis and prognosis. Rheumatology 51:77\u201386","journal-title":"Rheumatology"},{"key":"4086_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D et al (2017) Trial of Tocilizumab in giant-cell arteritis. N Engl J Med 377:317\u2013328","journal-title":"N Engl J Med"},{"key":"4086_CR11","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2003","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Segarra M, Vilardell C, S\u00e1nchez M, Garc\u00eda-Mart\u00ednez A, Esteban M-J et al (2003) Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107:2428\u20132434","journal-title":"Circulation"},{"key":"4086_CR12","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally L, Forbess L, Hatzis C, Spiera R (2016) Brief report: a prospective Open-Label Phase IIa Trial of Tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 68:2550\u20132554","journal-title":"Arthritis Rheumatol"},{"key":"4086_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/ard.2008.103663","volume":"69","author":"L Alvarez-Rodr\u00edguez","year":"2010","unstructured":"Alvarez-Rodr\u00edguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R et al (2010) Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 69:263\u2013269","journal-title":"Ann Rheum Dis"},{"key":"4086_CR14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","volume":"54","author":"KSM Geest van der","year":"2015","unstructured":"van der Geest KSM, Abdulahad WH, Rutgers A, Horst G, Bijzet J, Arends S et al (2015) Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology 54:1397\u20131402","journal-title":"Rheumatology"},{"key":"4086_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","volume":"121","author":"CM Weyand","year":"1994","unstructured":"Weyand CM, Hicok KC, Hunder GG, Goronzy JJ (1994) Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121:484\u2013491","journal-title":"Ann Intern Med"},{"key":"4086_CR16","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1002\/1529-0131(200011)43:11<2472::AID-ANR14>3.0.CO;2-B","volume":"43","author":"R Meliconi","year":"2000","unstructured":"Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C et al (2000) Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum 43:2472\u20132480","journal-title":"Arthritis Rheum"},{"key":"4086_CR17","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/rheumatology\/kex169","volume":"56","author":"G Carvajal Alegria","year":"2017","unstructured":"Carvajal Alegria G, Devauchelle-Pensec V, Renaudineau Y, Saraux A, Pers J-O, Cornec D (2017) Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica. Rheumatology 56:1401\u20131406","journal-title":"Rheumatology"},{"key":"4086_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0002-9440(10)65175-9","volume":"155","author":"M Kaiser","year":"1999","unstructured":"Kaiser M, Younge B, Bj\u00f6rnsson J, Goronzy JJ, Weyand CM (1999) Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 155:765\u2013774","journal-title":"Am J Pathol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4086-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4086-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T23:13:46Z","timestamp":1561504426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4086-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["4086"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4086-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"15 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interests. DC and MAC participated in the GiACTA study sponsored by Roche, without receiving personal fees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}